<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5782">
  <stage>Registered</stage>
  <submitdate>27/11/2012</submitdate>
  <approvaldate>27/11/2012</approvaldate>
  <nctid>NCT01737398</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy</studytitle>
    <scientifictitle>A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ISIS 420915-CS2</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>FAP</healthcondition>
    <healthcondition>Familial Amyloid Polyneuropathy</healthcondition>
    <healthcondition>TTR</healthcondition>
    <healthcondition>Transthyretin</healthcondition>
    <healthcondition>Amyloidosis</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IONIS-TTR Rx
Treatment: drugs - Placebo

Active Comparator: IONIS-TTR Rx - 

Active Comparator: Placebo - 


Treatment: drugs: IONIS-TTR Rx
300 mg IONIS-TTR Rx administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.

Treatment: drugs: Placebo
Placebo administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy of IONIS-TTR Rx as measured by change from baseline in the modified Neuropathy Impairment Score +7</outcome>
      <timepoint>65 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Efficacy of IONIS-TTR Rx as measured by change from baseline in the Norfolk Quality of Life Diabetic Neuropathy questionnaire</outcome>
      <timepoint>65 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy of IONIS-TTR Rx based on the change from baseline in the following measures: - Modified Body Mass Index and Body Mass Index
Individual components of the mNIS+7
NIS+7</outcome>
      <timepoint>65 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamic effect of IONIS-TTR Rx based on the change from baseline in transthyretin and retinol binding protein 4</outcome>
      <timepoint>65 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Stage 1 and Stage 2 FAP patients with the following:

               1. NIS score within protocol criteria

               2. Documented transthyretin variant by genotyping

               3. Documented amyloid deposit by biopsy

          -  Females of child-bearing potential must use appropriate contraception and must be
             non-pregnant and non-lactating. Males engaged in relations of child-bearing potential
             must use appropriate contraception</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>82</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Low Retinol level at screen

          -  Karnofsky performance status =50

          -  Poor Renal function

          -  Known type 1 or type 2 diabetes mellitus

          -  Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease)

          -  If previously treated with VyndaqelÂ®, must have discontinued treatment for 2 weeks
             prior to Study Day 1. If previously treated with Diflunisal, must have discontinued
             treatment for 3 days prior to Study Day 1

          -  Previous treatment with any oligonucleotide or siRNA within 12 months of screening

          -  Prior liver transplant or anticipated liver transplant within 1 yr of screening

          -  New York Heart Association (NYHA) functional classification of =3

          -  Acute Coronary Syndrome or major surgery within 3 months of screening

          -  Known Primary or Leptomeningeal Amyloidosis

          -  Anticipated survival less than 2 years

          -  Have any other conditions in the opinion of the investigator which could interfere
             with the patient participating in or completing the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>172</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Kremlin Bicetre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sicily</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisbon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ionis Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy and safety of IONIS-TTR Rx given for 65
      weeks in patients with Familial Amyloid Polyneuropathy</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01737398</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>